CD164

Chr 6q21

CD164 molecule

Aliases:: MUC-24, MGC-24, DFNA66, MGC-24v
MANE:: ENST00000310786.10

OMIM: 603356 ↗NCBI: 8763 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

CD164 · Q04900

v62025-08-01

Predicted Aligned Error matrix for CD164 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

66.6/ 100

Low

197 residues

Confidence breakdown

Very high(≥ 90)12%
Confident(70–90)32%
Low(50–70)33%
Very low(< 50)23%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

Monogenic hearing loss
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Disease associations (Open Targets)

clonal hematopoiesis
0.45
autosomal dominant nonsyndromic hearing loss
0.42
Abnormal central motor function
0.37
Alzheimer disease
0.28
intelligence
0.25
schizophrenia
0.25
Abnormality of the skeletal system
0.20
atrial fibrillation
0.18
lung carcinoma
0.15
aging
0.14

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Sialomucin core protein 24

Sialomucin that may play a key role in hematopoiesis by facilitating the adhesion of CD34(+) cells to the stroma and by negatively regulating CD34(+)CD38(lo/-) cell proliferation. Modulates the migration of umbilical cord blood CD133+ cells and this is mediated through the CXCL12/CXCR4 axis. May play an important role in prostate cancer metastasis and the infiltration of bone marrow by cancer cells. Promotes myogenesis by enhancing CXCR4-dependent cell motility. Positively regulates myoblast migration and promotes myoblast fusion into myotubes (By similarity)